Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial ….



Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial Activity of Bisphosphocin® Class Against Resistant Pathogens

Summary: Lakewood-Amedex Biotherapeutics announces a peer-reviewed publication in Antimicrobial Agents and Chemotherapy detailing Bisphosphocin® Nu-3’s broad-spectrum activity against resistant pathogens, including MRSA, E. coli, Pseudomonas, Klebsiella, and Acinetobacter. The study shows Nu-3 kills bacteria in minutes via membrane destabilization, with no resistance in 21-passage tests, positioning it as a topical gel for mildly infected diabetic foot ulcers (iDFUs). With 13 million U.S. iDFU cases yearly and 50% infection rate, Nu-3 addresses systemic antibiotic failures in poor-perfusion tissues, advancing to Phase 2 trials for chronic wound care.

Key Highlights:

  • Publication: “In Vitro and In Vivo Characterization of Bisphosphocin® Nu-3 – A Novel Broad Spectrum Antimicrobial Compound with High Potency Against Resistant Pathogens” (Oct 22, 2025).
  • Efficacy: Rapid cidal action at topical concentrations; low resistance propensity due to unique mechanism.
  • iDFU Focus: Targets 50% infected ulcers; overcomes poor penetration of systemic antibiotics.
  • Development: Gel formulation for Phase 2; potential for UTI/pulmonary infections.
  • Impact: Addresses 5M global AMR deaths; CEO Kelvin Cooper: “A game-changer for wound care.”

    • Read full article

    Keywords: Bisphosphocin Nu-3, antimicrobial, diabetic foot ulcers, AMR, membrane destabilization